Auspex Pharmaceuticals (NASDAQ: ASPX) is one of 290 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Auspex Pharmaceuticals to similar businesses based on the strength of its institutional ownership, risk, profitability, earnings, valuation, dividends and analyst recommendations.
This is a breakdown of recent ratings and price targets for Auspex Pharmaceuticals and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Auspex Pharmaceuticals Competitors||1175||3521||12062||248||2.67|
This table compares Auspex Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Auspex Pharmaceuticals Competitors||-5,346.13%||-159.26%||-35.94%|
Institutional & Insider Ownership
49.1% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Auspex Pharmaceuticals and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Auspex Pharmaceuticals Competitors||$290.27 million||$35.99 million||70.34|
Auspex Pharmaceuticals’ peers have higher revenue and earnings than Auspex Pharmaceuticals. Auspex Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Auspex Pharmaceuticals peers beat Auspex Pharmaceuticals on 6 of the 8 factors compared.
About Auspex Pharmaceuticals
Auspex Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people with movement disorders and other rare diseases, including orphan diseases. Its pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea (abnormal involuntary movements) associated with Huntington’s disease, an orphan disease, tardive dyskinesia and Tourette syndrome in the pediatric population, which is an orphan disease, as well as other orphan indications. Its lead product candidate is SD-809, which is a small molecule inhibitor of vesicular monoamine transporter 2 (VMAT2). Its other programs include SD-560, SD-1077 and SD-254.
Receive News & Ratings for Auspex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auspex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.